TNFRSF10B and neoplasm: Nab‐paclitaxel + anti‐PD‐L1 combinatorial immunotherapy orchestrates both immune‐independent and immune‐dependent anti‐tumor responses, respectively (Pardoll, 2012), while nab‐paclitaxel + anti‐DR5 therapy lacks immune activating component.